AMERSCAN MDP KIT
Clinical safety rating: caution
Comprehensive clinical and safety monograph for AMERSCAN MDP KIT (AMERSCAN MDP KIT).
Technetium-99m medronate is a bone-seeking radiopharmaceutical that localizes in bone by chemisorption to hydroxyapatite crystals, particularly in areas of increased osteoblastic activity.
| Metabolism | Technetium-99m medronate is not metabolized and is excreted unchanged by the kidneys. |
| Excretion | Renal: approximately 50-60% unchanged within 2-3 hours post-injection; biliary/fecal: negligible (<5%). The remainder is retained in bone (up to 40%) with slow release. |
| Half-life | Terminal elimination half-life: approximately 6 hours (range 4-8 hours) for the diphosphonate component; reflects clearance from bone and renal elimination. |
| Protein binding | Approximately 20-30% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Vd: 0.3-0.5 L/kg, indicating distribution into extracellular fluid and bone (hydroxyapatite). |
| Bioavailability | Intravenous: 100% (only route of administration). |
| Onset of Action | Intravenous: skeletal uptake begins within 30 minutes, with optimal imaging at 2-4 hours post-injection. |
| Duration of Action | Bone uptake persists for 4-6 hours; imaging window is 2-4 hours post-injection. Residual activity in bone may be detectable for up to 24 hours. |
Intravenous administration of 10-20 mCi (370-740 MBq) for adult bone imaging. Administer 2-4 hours prior to imaging.
| Dosage form | INJECTABLE |
| Renal impairment | Not formally established; due to renal excretion, consider reduced dose in severe renal impairment (eGFR <30 mL/min/1.73 m²) and delayed imaging to allow soft tissue clearance. |
| Liver impairment | No specific Child-Pugh based adjustments; hepatic dysfunction unlikely to alter pharmacokinetics as drug cleared renally. |
| Pediatric use | Weight-based: 100-200 µCi/kg (3.7-7.4 MBq/kg) intravenously, administered 2-4 hours prior to imaging. Minimum dose 1 mCi (37 MBq). |
| Geriatric use | No specific adjustments required; use standard adult dose with careful monitoring of renal function due to age-related decline. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for AMERSCAN MDP KIT (AMERSCAN MDP KIT).
| Breastfeeding | Breastfeeding should be interrupted for at least 24 hours after administration. No M/P ratio available; technetium-99m is excreted in breast milk in small amounts. Advise pump and discard milk for 24 hours. |
| Teratogenic Risk | Teratogenic risk is not established; technetium-99m labeled phosphonates cross the placenta. First trimester: avoid unless benefit outweighs risk due to potential fetal radiation exposure (fetal dose ~0.003-0.006 mGy/MBq). Second/third trimester: risk from radiation is lower, but still use only if necessary. |
■ FDA Black Box Warning
None.
| Serious Effects |
Hypersensitivity to any component of the kit.
| Precautions | Radiopharmaceuticals should be used with caution in pregnant women and during lactation. Ensure adequate patient hydration and frequent voiding to minimize radiation exposure to bladder and gonads. Allergic reactions, including anaphylaxis, may occur. Radiation exposure risk. |
| Food/Dietary | No specific food interactions. Maintain hydration; avoid caffeine or alcohol before the scan as they may affect hydration status. |
| Clinical Pearls |
Loading safety data…
| Fetal Monitoring |
| No specific maternal-fetal monitoring required beyond standard radiation safety precautions. Ensure adequate hydration to promote voiding and reduce radiation exposure. |
| Fertility Effects | No known adverse effects on fertility from the radiopharmaceutical. Radiation exposure from diagnostic imaging is generally below thresholds affecting fertility. |
| Amerscan MDP Kit (technetium Tc-99m medronate) is a bone imaging agent. Ensure adequate patient hydration before and after injection to enhance renal clearance and reduce radiation dose to bladder. Use within 6 hours of Tc-99m labeling. Note that inflammatory or neoplastic bone lesions show increased uptake; delayed imaging (2-4 hours post-injection) improves specificity. Avoid extravasation as it causes false-positive uptake. In renal impairment, image quality may degrade due to poor clearance. |
| Patient Advice | Drink plenty of water before and after the scan to help flush the radioactive material out of your body. · You may need to empty your bladder frequently to reduce radiation exposure. · This test involves a small amount of radiation; the risk is low compared to the benefit of diagnosis. · Inform your doctor if you are pregnant or breastfeeding. · You may experience mild discomfort at the injection site. |